Coherus Oncology Showcases Multiomic Biomarker Data for CHS-114, a Selective Anti-CCR8 Cytolytic Antibody, at SITC Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Should l Buy CHRS?
Source: Newsfilter
CHS-114 Clinical Trial Results: Coherus Oncology's CHS-114, an anti-CCR8 antibody, showed effective depletion of CCR8+ Tregs and increased CD8 T cells in head and neck squamous cell carcinoma (HNSCC) patients, indicating promising immune remodeling and antitumor activity.
Combination Therapy with Toripalimab: The combination of CHS-114 with toripalimab resulted in enhanced immune activation and a significant increase in CD8+ T cell proliferation, supporting further development of this treatment strategy in advanced solid tumors.
Safety Profile and Efficacy: The ongoing Phase 1b trial demonstrated a manageable safety profile for CHS-114, with early signs of antitumor activity, including a partial response in a refractory HNSCC patient.
Future Development Plans: Coherus aims to optimize dosing for CHS-114 in combination with toripalimab, addressing FDA's Project Optimus and advancing to Phase 2 trials based on the promising results from the current study.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CHRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CHRS
Wall Street analysts forecast CHRS stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.010
Low
4.00
Averages
5.50
High
7.00
Current: 2.010
Low
4.00
Averages
5.50
High
7.00
About CHRS
Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Coherus Oncology Prices $50.1 Million Public Offering
- Funding Size: Coherus Oncology has priced an underwritten public offering of 28.6 million shares at $1.75 each, raising a total of $50.1 million, with the transaction expected to close on February 17, 2026, aimed at supporting the commercialization of LOQTORIZ and ongoing clinical development.
- Revenue Growth: The company reported Q3 2025 net revenue of $11.6 million, a significant increase from $6.05 million in the previous quarter, reflecting strong market demand for LOQTORIZ and a recovery in overall business performance.
- Clinical Trial Results: LOQTORIZ demonstrated a median overall survival of 64.8 months in the JUPITER-02 trial, nearly double that of chemotherapy alone, reinforcing its position as the standard-of-care first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
- Future Milestones: Coherus plans to release initial data from the CHS-114 and LOQTORIZ combination therapy in HNSCC in H1 2026, which is expected to drive further development of its immuno-oncology programs and enhance its competitive edge in the market.
See More
Applied Materials Reports Strong Q1 Results, Shares Surge
- Strong Financial Results: Applied Materials reported first-quarter revenue of $7.01 billion, exceeding analyst expectations of $6.87 billion, indicating robust demand in the semiconductor equipment market and reinforcing its market leadership.
- Earnings Beat: The company posted adjusted earnings of $2.38 per share for the first quarter, surpassing the $2.20 estimate, reflecting improved cost control and operational efficiency, which is likely to attract more investor interest.
- Stock Surge: Following the earnings report, Applied Materials shares jumped 11.9% to $367.50 in pre-market trading, indicating a positive market sentiment towards the company's growth prospects, potentially boosting investor confidence further.
- Positive Q2 Guidance: The company issued second-quarter guidance above market expectations, demonstrating management's confidence in future performance, which is expected to drive more capital inflows and enhance its competitive position in the industry.
See More
Coherus Oncology Prices Public Offering at $1.75 per Share
- Offering Size: Coherus Oncology has priced an underwritten public offering of 28.6 million shares at $1.75 per share, expecting to raise approximately $50.1 million in gross proceeds before fees and expenses, indicating the company's strong capital market capabilities.
- Underwriter Option: The company is also granting underwriters a 30-day option to purchase an additional 4.29 million shares at the same price, a strategy that may enhance market demand and liquidity for its stock.
- Use of Proceeds: The net proceeds will support the commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of its pipeline, and fund working capital and other general corporate purposes, demonstrating the company's strategic planning for future growth.
- Expected Closing Date: The offering is expected to close around February 17, 2026, subject to standard closing conditions, reflecting the company's cautious and forward-looking approach to capital operations.
See More
Coherus Oncology Prices Public Offering at $1.75 per Share
- Offering Size: Coherus Oncology has announced a public offering of 28,600,000 shares at a price of $1.75 per share, with expected gross proceeds of approximately $50.1 million, which will support ongoing commercialization and clinical development efforts.
- Underwriter Selection: The offering is being managed by TD Cowen, Guggenheim Securities, and Oppenheimer & Co., reflecting market confidence in Coherus' stock and potentially enhancing investor expectations for the company's future growth.
- Use of Proceeds: The proceeds from the offering will be utilized to support the commercialization of LOQTORZI®, continue clinical development, and for general corporate purposes, indicating strategic decisions aimed at expanding the company's product line and market share.
- Additional Share Option: The underwriters have a 30-day option to purchase an additional 4,290,000 shares at the same offering price, which further enhances the flexibility and potential revenue of the offering.
See More
Johnson & Johnson Partners with Coherus for Cancer Trial
- Clinical Trial Collaboration: Johnson & Johnson (JNJ) has agreed to supply Coherus Oncology (CHRS) with its bispecific antibody pasritamig to evaluate its combination with Coherus' monoclonal antibody tagmokitug for a phase 1b trial in metastatic castration-resistant prostate cancer, highlighting the synergistic potential in cancer treatment between the two companies.
- Trial Funding Arrangement: Coherus will sponsor the phase 1b clinical trial, which not only provides a crucial clinical validation opportunity for its product tagmokitug but also has the potential to enhance its market competitiveness through successful trial outcomes.
- Retention of Commercial Rights: Both companies will retain commercial rights to each other's compounds, whether as monotherapies or combination therapies, which helps facilitate independent brand development while laying the groundwork for future collaborations.
- Antibody Characteristics: Pasritamig is considered a T-cell engaging bispecific antibody, while tagmokitug is an anti-CCR8 cytolytic monoclonal antibody, and this technological combination may offer new treatment options for prostate cancer patients, further driving innovation in the biopharmaceutical sector for both companies.
See More
Oncolytics Biotech Strengthens Leadership Amid Oncology Market Surge
- Market Potential: The global oncology therapy market is projected to reach $668 billion by 2034, and Oncolytics Biotech is seizing investment opportunities through execution-focused registration study designs in this rapidly growing sector.
- Leadership Enhancement: Oncolytics Biotech appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to advance the company's registration-directed programs in gastrointestinal cancers.
- Breakthrough Efficacy Data: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients, significantly surpassing the historical 6-11% response rate for chemotherapy alone, indicating its potential in difficult-to-treat populations.
- FDA Study Design Approval: Oncolytics Biotech has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the imminent launch of the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
Coherus Oncology Prices $50.1 Million Public Offering
- Funding Size: Coherus Oncology has priced an underwritten public offering of 28.6 million shares at $1.75 each, raising a total of $50.1 million, with the transaction expected to close on February 17, 2026, aimed at supporting the commercialization of LOQTORIZ and ongoing clinical development.
- Revenue Growth: The company reported Q3 2025 net revenue of $11.6 million, a significant increase from $6.05 million in the previous quarter, reflecting strong market demand for LOQTORIZ and a recovery in overall business performance.
- Clinical Trial Results: LOQTORIZ demonstrated a median overall survival of 64.8 months in the JUPITER-02 trial, nearly double that of chemotherapy alone, reinforcing its position as the standard-of-care first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
- Future Milestones: Coherus plans to release initial data from the CHS-114 and LOQTORIZ combination therapy in HNSCC in H1 2026, which is expected to drive further development of its immuno-oncology programs and enhance its competitive edge in the market.
See More
Applied Materials Reports Strong Q1 Results, Shares Surge
- Strong Financial Results: Applied Materials reported first-quarter revenue of $7.01 billion, exceeding analyst expectations of $6.87 billion, indicating robust demand in the semiconductor equipment market and reinforcing its market leadership.
- Earnings Beat: The company posted adjusted earnings of $2.38 per share for the first quarter, surpassing the $2.20 estimate, reflecting improved cost control and operational efficiency, which is likely to attract more investor interest.
- Stock Surge: Following the earnings report, Applied Materials shares jumped 11.9% to $367.50 in pre-market trading, indicating a positive market sentiment towards the company's growth prospects, potentially boosting investor confidence further.
- Positive Q2 Guidance: The company issued second-quarter guidance above market expectations, demonstrating management's confidence in future performance, which is expected to drive more capital inflows and enhance its competitive position in the industry.
See More
Coherus Oncology Prices Public Offering at $1.75 per Share
- Offering Size: Coherus Oncology has priced an underwritten public offering of 28.6 million shares at $1.75 per share, expecting to raise approximately $50.1 million in gross proceeds before fees and expenses, indicating the company's strong capital market capabilities.
- Underwriter Option: The company is also granting underwriters a 30-day option to purchase an additional 4.29 million shares at the same price, a strategy that may enhance market demand and liquidity for its stock.
- Use of Proceeds: The net proceeds will support the commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of its pipeline, and fund working capital and other general corporate purposes, demonstrating the company's strategic planning for future growth.
- Expected Closing Date: The offering is expected to close around February 17, 2026, subject to standard closing conditions, reflecting the company's cautious and forward-looking approach to capital operations.
See More
Coherus Oncology Prices Public Offering at $1.75 per Share
- Offering Size: Coherus Oncology has announced a public offering of 28,600,000 shares at a price of $1.75 per share, with expected gross proceeds of approximately $50.1 million, which will support ongoing commercialization and clinical development efforts.
- Underwriter Selection: The offering is being managed by TD Cowen, Guggenheim Securities, and Oppenheimer & Co., reflecting market confidence in Coherus' stock and potentially enhancing investor expectations for the company's future growth.
- Use of Proceeds: The proceeds from the offering will be utilized to support the commercialization of LOQTORZI®, continue clinical development, and for general corporate purposes, indicating strategic decisions aimed at expanding the company's product line and market share.
- Additional Share Option: The underwriters have a 30-day option to purchase an additional 4,290,000 shares at the same offering price, which further enhances the flexibility and potential revenue of the offering.
See More
Johnson & Johnson Partners with Coherus for Cancer Trial
- Clinical Trial Collaboration: Johnson & Johnson (JNJ) has agreed to supply Coherus Oncology (CHRS) with its bispecific antibody pasritamig to evaluate its combination with Coherus' monoclonal antibody tagmokitug for a phase 1b trial in metastatic castration-resistant prostate cancer, highlighting the synergistic potential in cancer treatment between the two companies.
- Trial Funding Arrangement: Coherus will sponsor the phase 1b clinical trial, which not only provides a crucial clinical validation opportunity for its product tagmokitug but also has the potential to enhance its market competitiveness through successful trial outcomes.
- Retention of Commercial Rights: Both companies will retain commercial rights to each other's compounds, whether as monotherapies or combination therapies, which helps facilitate independent brand development while laying the groundwork for future collaborations.
- Antibody Characteristics: Pasritamig is considered a T-cell engaging bispecific antibody, while tagmokitug is an anti-CCR8 cytolytic monoclonal antibody, and this technological combination may offer new treatment options for prostate cancer patients, further driving innovation in the biopharmaceutical sector for both companies.
See More
Oncolytics Biotech Strengthens Leadership Amid Oncology Market Surge
- Market Potential: The global oncology therapy market is projected to reach $668 billion by 2034, and Oncolytics Biotech is seizing investment opportunities through execution-focused registration study designs in this rapidly growing sector.
- Leadership Enhancement: Oncolytics Biotech appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to advance the company's registration-directed programs in gastrointestinal cancers.
- Breakthrough Efficacy Data: The company reported that pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite stable metastatic colorectal cancer patients, significantly surpassing the historical 6-11% response rate for chemotherapy alone, indicating its potential in difficult-to-treat populations.
- FDA Study Design Approval: Oncolytics Biotech has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the imminent launch of the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
